85592-76-3Relevant academic research and scientific papers
OXAZOLIDINONE DERIVATIVES AS PPAR LIGANDS
-
Paragraph 0150; 0167, (2016/06/28)
The present invention relates to a family of differently substituted oxazolidinones and to the pharmaceutically acceptable salts, esters, prodrugs, tautomers, solvates and hydrates thereof, which show affinity for the alpha and gamma subtypes of the perox
Novel Oxazolidinone-Based Peroxisome Proliferator Activated Receptor Agonists: Molecular Modeling, Synthesis, and Biological Evaluation
Fresno,Macías-González,Torres-Zaguirre,Romero-Cuevas,Sanz-Camacho,Elguero,Pavón,Rodríguez De Fonseca,Goya,Pérez-Fernández
, p. 6639 - 6652 (2015/09/07)
(Figure Presented). A series of new peroxisome proliferator activated receptors (PPARs) chiral ligands have been designed following the accepted three-module structure comprising a polar head, linker, and hydrophobic tail. The majority of the ligands inco
Benzamide therapeutics for the treatment of inflammatory bowel disease
-
, (2008/06/13)
Benzamides are disclosed to be useful for treating and preventing inflammatory bowel disease.
Aminobenzamide compounds for the treatment of neurodegenerative disorders
-
, (2008/06/13)
A group of benzamide compounds are disclosed which are useful for treating neurodegenerative disorders. Methods for making these compounds are provided. These materials are formed into pharmaceutical compositions for oral or intravenous administration to patients suffering from conditions such as Parkinson's disease which can exhibit themselves as progressive loss of central nervous system function. The compounds can arrest or slow the progressive loss of function.
Anticonvulsant activity of some 4-aminobenzamides
Clark,Wells,Sansom,et al.
, p. 779 - 782 (2007/10/02)
A series of 4-aminobenzamides of some simple primary and secondary amines were prepared and evaluated for anticonvulsant effects. The compounds were tested in mice against seizures induced by electroshock and pentylenetetrazole (metrazole) and in the rotorod assay for neurologic deficit. For those N-alkyl amides tested, 4-amino-N-amylbenzamide was the most potent against maximal electroshock seizures (MES): ED50=42.98 mg/kg; however, the N-cyclohexylbenzamide showed the greatest protective index (PI=TD50/ED50), 2.8. The introduction of a second aromatic ring produced more potent compounds, with d,l-4-amino-N-(α-methylbenzyl)-benzamide showing the highest level of activity. This compound has an anti-MES ED50 of 18.02 mg/kg in mice when administered intraperitoneally (ip) and a TD50 of 170.78 mg/kg (PI=9.5) in the same species. These data compare quite favorably with those for phenobarbital and phenytoin in the same assays.
Anti-convulsant
-
, (2008/06/13)
New amino-benzamides and their use for the treatment of epilepsy.
